Hendy Abdelaziz, Ibrahim Rasha Kadri, Darwish Amani, Al Sabbah Saher, Shalby Abeer Yahia Mahdy, Khubrani Rahmah, Alawad Amal Elhaj, Abdelaliem Sally Mohammed Farghaly, Wahba Nadia Mohamed Ibrahim
Pediatric Nursing, Faculty of Nursing, Ain Shams University, Cairo, Egypt.
Nursing Department, Fatima College of Health Sciences, Al Dhafra region, Baynunah complex, Madinat Zayed, Abu Dhabi, 50433, UAE.
BMC Cancer. 2025 Jul 1;25(1):1122. doi: 10.1186/s12885-025-14538-6.
This study aims to assess effect of sleep disturbance, cancer-related fatigue, and depression on the quality of life (QoL) of breast cancer patients undergoing chemotherapy.
A descriptive, cross-sectional study was conducted at an oncology hospital in Cairo, Egypt, from November 2024 to February 2025. A total of 253 breast cancer patients undergoing chemotherapy were recruited through convenience sampling. Data were collected using validated instruments: Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Therapy-Breast (FACT-B), Cancer Fatigue Scale (CFS), and Patient Health Questionnaire-9 (PHQ-9) for depression. Linear regression models were employed to analyze the relationships between sleep disturbance, fatigue, depression, and QoL.
Findings revealed that 99.2% of patients experienced fatigue, 87.4% reported poor sleep, and 93.3% exhibited depressive symptoms. Regression analysis demonstrated that sleep disturbance had the strongest negative impact on QoL ( = -1.506, < 0.001), overshadowing both fatigue and depression. Correlation analysis further supported these findings, with sleep disturbance showing the highest negative correlation with QoL ( = -0.81, < 0.001), followed by fatigue ( = -0.72, < 0.001) and depression ( = -0.56, < 0.001).
Sleep disturbance, cancer-related fatigue, and depression are significantly associated with reduced QoL in breast cancer patients undergoing chemotherapy. Among these factors, sleep disturbance appears to be the most influential. Interventions targeting sleep quality may help mitigate related psychological and physical challenges, thereby enhancing patients’ overall well-being.
The online version contains supplementary material available at 10.1186/s12885-025-14538-6.
本研究旨在评估睡眠障碍、癌症相关疲劳和抑郁对接受化疗的乳腺癌患者生活质量（QoL）的影响。
2024年11月至2025年2月在埃及开罗的一家肿瘤医院进行了一项描述性横断面研究。通过便利抽样招募了总共253名接受化疗的乳腺癌患者。使用经过验证的工具收集数据：匹兹堡睡眠质量指数（PSQI）、癌症治疗功能评估-乳腺癌（FACT-B）、癌症疲劳量表（CFS）以及用于评估抑郁的患者健康问卷-9（PHQ-9）。采用线性回归模型分析睡眠障碍、疲劳、抑郁与生活质量之间的关系。
研究结果显示，99.2%的患者经历疲劳，87.4%报告睡眠不佳，93.3%表现出抑郁症状。回归分析表明，睡眠障碍对生活质量的负面影响最大（β = -1.506，P < 0.001），超过了疲劳和抑郁。相关性分析进一步支持了这些结果，睡眠障碍与生活质量的负相关性最高（r = -0.81，P < 0.001），其次是疲劳（r = -0.72，P < 0.001）和抑郁（r = -0.56，P < 0.001）。
睡眠障碍、癌症相关疲劳和抑郁与接受化疗的乳腺癌患者生活质量降低显著相关。在这些因素中，睡眠障碍似乎最具影响力。针对睡眠质量的干预措施可能有助于减轻相关的心理和身体挑战，从而提高患者的整体幸福感。
在线版本包含可在10.1186/s12885-025-14538-6获取的补充材料。
